GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (TSX:APS) » Definitions » Beta

Aptose Biosciences (TSX:APS) Beta : 0.46 (As of Mar. 14, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Aptose Biosciences Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2025-03-14), Aptose Biosciences's Beta is 0.46.


Aptose Biosciences Beta Historical Data

The historical data trend for Aptose Biosciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences Beta Chart

Aptose Biosciences Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 1.36 1.14 1.62 1.43

Aptose Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.37 1.43 1.13 1.30 0.98

Competitive Comparison of Aptose Biosciences's Beta

For the Biotechnology subindustry, Aptose Biosciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptose Biosciences's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptose Biosciences's Beta distribution charts can be found below:

* The bar in red indicates where Aptose Biosciences's Beta falls into.



Aptose Biosciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Aptose Biosciences  (TSX:APS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Aptose Biosciences Beta Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptose Biosciences Business Description

Traded in Other Exchanges
Address
251 Consumers Road, Suite 1105, Toronto, ON, CAN, M2J 4R3
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Executives
Bernd Robert Seizinger Director
William Glenn Rice Director, Senior Officer
Erich Platzer Director
Rafael Bejar Senior Officer
Warren Whitehead Director
Gregory Kwok Lee Chow Senior Officer
Jotin Marango Senior Officer

Aptose Biosciences Headlines

No Headlines